Home/Filings/4/0001209191-22-029323
4//SEC Filing

Lavelle Erin 4

Accession 0001209191-22-029323

CIK 0001404644other

Filed

May 15, 8:00 PM ET

Accepted

May 16, 6:23 PM ET

Size

9.2 KB

Accession

0001209191-22-029323

Insider Transaction Report

Form 4
Period: 2022-05-12
Lavelle Erin
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-05-12+25,00025,000 total
    Exercise: $1.07Exp: 2032-05-11Common Stock (25,000 underlying)
Footnotes (1)
  • [F1]The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Issuer

Neoleukin Therapeutics, Inc.

CIK 0001404644

Entity typeother

Related Parties

1
  • filerCIK 0001737613

Filing Metadata

Form type
4
Filed
May 15, 8:00 PM ET
Accepted
May 16, 6:23 PM ET
Size
9.2 KB